



www.osakidetza.euskadi.eus/cevime



LISDEXANFETAMINA

BIBLIOGRAFÍA

1. Ficha técnica lisdexanfetamina. Elvanse®. Shire Pharmaceutical Contracts Limited. Disponible en: http://www.aemps.gob.es/cima/pdfs/es/ft/77643/FT_77643.pdf
2. Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD) European Medicines Agency. 22 July 2010 EMEA/CHMP/EWP/431734/2008. Committee for Medicinal Products for Human use (CHMP) Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/08/WC500095686.pdf
3. Medicines and Healthcare Products Regulatory Agency. Public Assessment Report. Elvanse 30 mg, 50 mg y 70 mg capsules, hard. Lisdexamfetamine dimesylate. UK/H/3326/001-03/DC.2013. Disponible en: <http://www.mhra.gov.uk/home/groups/par/documents/websitesources/con261790.pdf>
4. Dittmann RW et al. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs [Epub ahead of print] 20 August 2013; DOI:10.1007/S40263-013-0104-8.
5. Coghill D et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol [Epub ahead of print] 17 January 2013; DOI:10.1016/j.euroneuro.2012.11.012.
6. Coghill D, Banaschewski T, Lecendreux M, Johnson M et al. Maintenance of Efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/Hyperactivity disorder: randomized-withdrawal study design. Journal of the American Academy of child and adolescent psychiatry. Vol 53. Num 6. June 2014
7. L A. Adler, MD; Dirks B, MD; Deas P, BS; Raychaudhuri A, PhD; Dauphin M ,MS et al. Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/ Hyperactivity Disorder Who Report Clinically Significant Impairment in Executive Function: Results From a Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychiatry 2013;74(7):694-702
8. Biederman J et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 2007; 62: 970-6.
9. Biederman J et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase iii, multicentre, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 2007; 3: 450-63.
10. Findling RL et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011; 50: 395-405.
11. Wigal S et al. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health 2009; 3: 17.
12. SPD489-316
13. Findling RL, Childress AC, Krishnan S and McGough J. Long-Term Effectiveness and Safety of Lisdexamfetamine Dimesylate in School-Aged Children with Attention-Deficit/Hyperactivity Disorder. CNS Spectr. 2008 Jul;13(7):614-20
14. Findling RL, Cutler AJ, Saylor K, Gasior M, Hamdani M, Ferreira-Cornwell MC, Childress AC. A Long-Term Open-Label Safety and Effectiveness Trial of Lisdexamfetamine Dimesylate in Adolescents With Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology. February 2013, 23(1): 11-21.
15. Guía de Práctica Clínica sobre el Trastorno por Déficit de Atención con Hiperactividad (TDAH) en Niños y Adolescentes. Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad, Política Social e Igualdad. Agència d'Informació, Avaluació i Qualitat en Salut (AIAQS) de Catalunya; 2010. Guías de Práctica Clínica en el SNS: AIAQS Nº 2007/18.
16. Attention déficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. National Institute for Care and Health and clinical Excellence (NICE) clinical guideline 72. Last modified March 2013. Disponible en: <http://www.nice.org.uk/guidance/cg72/resources/guidance-attention-deficit-hyperactivity-disorder-pdf>
17. Scottish intercollegiate guidelines Network (SIGN). Management of attention deficit and hyperkinetic disorders in children and young people. National clinical guideline. October 2009.
18. Protocol de tractament del TDAH. Àrea Integral de Salut Barcelona Nord. Consorci Sanitari de Barcelona. Disponible en: http://www.gencat.cat/salut/botss/html/ca/dir2887/tractament_tdah_bcn_nord.pdf